In that study, we implemented cutting-edge imaging techniques, such as multiparametric magnetic resonance imaging (mpMRI), which has been shown to improve the sensitivity and specificity in detecting and characterizing high-risk PCa foci [19], as well as 68Ga-labeled prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (68Ga-PSMA-PET/CT) in order to determine the site of recurrence and compare it to the original site of tumor development. The gene discussed is FOLH1; the disease is neoplasm.